Liver dysfunction is a common problem in BMT recipients and it is important to determine the etiology in order to institute appropriate therapy. The purpose of this study was to evaluate the possible causes of liver dysfunction during the first post-transplant year in BMT recipients and to identify a possible relationship between pre-existing liver dysfunction and viral hepatitis with prognosis after BMT. We reviewed liver status before and after BMT in 130 consecutive patients at the Catholic Hematopoietic Stem Cell Transplantation Center. Liver dysfunction during the first post-transplant year occurred in 85 out of 101 (84.2%) allogeneic BMT recipients and 13 out of 29 (44.8%) autologous BMT recipients. In allogeneic BMT, GVHD and drug hepatotoxicity were major causes. In autologous BMT, drug hepatotoxicity was the most common cause. Eighteen out of 130 patients (13.8%) had abnormal liver function tests before BMT. These patients did not have an increased risk of post-transplant liver dysfunction, GVHD, and death compared to patients who had normal liver function tests prior to BMT. Nine patients were hepatitis B antigen positive and three patients were anti-HCV positive prior to BMT. There was no significant increase in the incidence of post-transplant liver dysfunction, GVHD, and death in these patients. Bone Marrow Transplantation (2000) 26, 193-197. 
There is an increasing role of bone marrow transplantation (BMT) in the management of hematological malignancies and non-hematological solid tumors. Early survival after transplantation is largely dependent on whether complications involving the liver, lung and intestine occur, and whether fatal infection can be avoided. Hepatic dysfunction following BMT may be due to a variety of causes including infections, drugs, hepatic veno-occlusive disease (VOD), graft-versus-host disease (GVHD), viral hepatitis, and relapse. clinical setting in which liver dysfunction occurs. Often, more than one possible cause of liver dysfunction may be identifiable. There has been some recently published data regarding the cause of liver dysfunction after BMT. 2, 3 Korea is one of the hepatitis B virus (HBV) endemic areas and 7-8% of the Korean population are HBV carriers. 4 Liver dysfunction often occurs in patients with hematological malignancies before BMT. However, the risk of BMT with liver dysfunction is not well defined. Controversy continues regarding the significance of liver disease in patients with liver dysfunction prior to BMT. 5, 6 Also the roles of hepatitis B surface antigen [7] [8] [9] and anti-hepatitis C virus positivity 10 prior to BMT are not well defined. Therefore, we carried out a retrospective study to evaluate the possible causes of liver dysfunction during the first post-transplanat year in allogeneic and autologous BMT recipients and to identify a possible relationship between pre-existing liver function abnormality and viral hepatitis with prognosis after BMT.
Patients and methods

Patients
Between August 1996 and July 1997, 101 allogeneic and 29 autologous BMTs were performed at the Catholic Hematopoietic Stem Cell Transplantation Center. For allogeneic BMT, patients and siblings were HLA typed. HLA A, B, C, and DR loci were examined and fully matched siblings were selected as donors. Patient characteristics including diagnosis and conditioning regimens are provided in Table 1 . GVHD prophylaxis was with methotrexate and cyclosporine. Gut decontamination was with ciprofloxacin and fluconazole.
Liver function tests
Hepatitis B surface antigen (HBs Ag) and hepatitis B surface antibody (HBsAb) were assayed by radio-immunoassay (Abbott Laboratories, Abbott Park, IL, USA). An enzyme-linked immunosorbant assay (Abbott Laboratories) was used for detection of hepatitis C virus antibody. Alanine aminotransferase (ALT), alkaline phosphatase, and total bilirubin were measured by automated chemical analysis using standard reagents. The normal range is 35 IU/l for ALT, below 254 for alkaline phosphatase, and below 1.2 mg/dl for total bilirubin, respectively. 
Hepatic dysfunction
The medical records of all patients were reviewed and details of serial liver function tests during the pre-and posttransplant period were evaluated. These data were collected and analyzed for specific time periods after transplantation: 1 to 30 days, 31 to 100 days, and 101 to 365 days. For most patients, liver function tests were carried out twice weekly during the first 30 days, once a week during the next 30 to 60 days, once a month after 60 days to 180 days, and every 2 months after 180 days to 1 year. Note was made of relevant clinical findings and subsequent investigations. The etiology of abnormal liver function and any therapeutic action taken were recorded.
Diagnostic criteria
Diagnostic criteria of causes of abnormal liver function are outlined below using the criteria of Forbes et al. 
Results
Survival rate
After 1 year following BMT, 65 out of 101 (64.4%) allogeneic and 25 out of 29 (86.2%) autologous BMT recipients were alive. Six allogeneic and no autologous recipients died during the first 30 days, 16 allogeneic and no autologous recipients died between 30 and 100 days, and 13 allogeneic and three autologous recipients died from 100 days to 1 year. One allogeneic and one autologous patient were lost to follow-up. The causes of death are summarized in Table 2 . Fulminant hepatic failure occurred in seven out of 101 allogeneic recipients (6.9%) and none of the autologous BMT recipients. The etiology of fulminant hepatic failure was hepatic GVHD in four patients, hepatic GVHD combined with viral hepatitis B in one patient, and sepsis in two patients.
Incidence of liver dysfunction
Liver function abnormality occurred in 93 out of 130 (71.5%) during the first post-BMT year. Eighty-five out of 101 (84.2%) allogeneic recipients and 13 out of 29 (44.8%) autologous recipients had abnormal liver function test. Liver function abnormality occurred in about 50% of allogeneic recipients during each post-transplantation period. By contrast, abnormal liver function was noted mainly during the first 30 days in autologous recipients (Figure 1 ).
Etiology
The main cause of hepatic dysfunction in autologous recipients was drug hepatotoxicity (Table 3 ). In allogeneic recipients, GVHD and drug hepatotoxicity were major causes of liver dysfunction. Prednisolone was the drug most often implicated. Viral hepatitis, veno-occlusive disease, and sepsis were less than 10% (Table 3 ). The incidence of drug toxicity decreased gradually during the first post-BMT year (Figure 2 ). More than one cause of abnormal liver function was identifiable in 26 out of 130 (20%) transplant recipients. GVHD with infection, VOD, or drug effect were common events. In eight instances, the cause was not determined.
Liver function abnormality prior to BMT
Eighteen out of 130 recipients (13.8%) had liver function abnormalities before BMT. The ALT was 70.7 ± 16.8 IU/l, total bilirubin 0.8 ± 0.5 mg/dl, and alkaline phosphatase was 286.9 ± 30.9 U/l (mean ± 2 s.d.). Only one out of 18 patients had positive HBV markers and two out of 18 patients had positive HCV antibody before BMT. Drug toxicity was presumed in five patients and the etiology of the other 10 patients could not be determined. There was no significant difference in the incidence of post-transplant liver dysfunction, GVHD, fulminant hepatic failure, and death rate in the patients with liver function abnormality (Table 4 ) compared to patients with normal liver function prior to BMT.
Clinical outcome of BMT in patients with hepatitis B surface antigen or anti-HCV positivity
Nine out of 130 patients were HBs Ag positive and three were anti-HCV positive before transplantation. Prior to BMT, only one patient out of nine had elevated levels of ALT, total bilirubin, or alkaline phosphatase and the other eight patients had normal liver function tests. Two out of three anti-HCV positive patients had elevated liver function tests. Patients with HBs Ag or HCV antibody positive had no significant difference in the incidence of the post-transplant liver dysfunction, GVHD, fulminant hepatic failure, and death (Table 5 ).
Incidence and prognosis of hepatic GVHD
Hepatic GVHD developed in 41 out of 101 allogeneic transplant recipients (40.6%). Acute hepatic GVHD occurred in 25 patients and chronic GVHD occurred in 16. Patients with hepatic GVHD had a higher incidence of death (Table 6 ). Laparascopic liver biopsy was performed in eight allogeneic recipients. Four transplant recipients required a biopsy to differentiate between GVHD and viral hepatitis. The other four patients required a biopsy to differentiate between GVHD and cyclosporin toxicity.
Discussion
This study shows that the incidence of liver function abnormalities following BMT is 71.5% and this incidence is similar to previous reports. 3 Although many etiologies are responsible, GVHD and drug hepatotoxicity were the main causes of liver function abnormality among allogeneic recipients. Forbes et al 2 reported that disease recurrence and sepsis were the most common causes of abnormal liver function in autologous BMT but our study shows that drug hepatotoxicity was the most common cause. 
Table 6
The prognosis of hepatic graft-versus-host disease (GVHD) in 101 allogeneic transplants Times after BMT were arbitrarily divided into three periods: 1-30 days, 31-100 days, and 101-365 days after BMT, because veno-occlusive disease and drug hepatotoxicity due to conditioning regimens are mainly observed during the first 30 days, 2, 12 and acute and chronic GVHD are distinguished by 100 days after BMT. 13 It is important to determine the etiology of liver function abnormalities in order to institute appropriate therapy. In our study, the diagnostic process was accomplished by interpretation of the clinical setting in which liver function abnormality occurred, in conjunction with relatively simple and non-invasive investigations. Laparascopic liver biopsy was performed in eight out of 130 (6.2%) transplant recipients because of persistent abnormal liver function, which did not improve with conservative medical management. It is not feasible to achieve histological confirmation on a regular basis in these patients. Over the past few years, laparoscopic liver biopsy has been used increasingly in evaluating liver dysfunction in immunocompromised, thrombocytopenic patients.
14 It is difficult to separate the hepatic effects of GVHD from those of cyclosporin toxicity or viral hepatitis. In our eight patients who underwent laparoscopic biopsy, seven were consistent with GVHD and one with viral hepatitis.
It is difficult to diagnose drug hepatotoxicity because many drugs used during the BMT procedure can cause liver dysfunction. Cyclosporin can cause necrosis of zone 3 hepatocytes and can potentiate chemoradiation hepatotoxicity. 15 Methotrexate, prednisolone, azathioprine, and antibiotics such as ketoconazole and sulfamethoxazole can cause liver dysfunction. 1 We were suspicious of these drugs as causing hepatotoxicity, and liver function abnormalities improved after such drugs were discontinued or reduced.
The question addressed by the present study was whether pre-BMT liver function abnormalities are an important prognostic factor for post-transplant liver dysfunction and death. Various observations suggest that patients with liver dysfunction before transplantation may be at increased risk of hepatic disease after BMT. 5, 7 Others reported that hepatic disease at the time of transplantation did not appear to increase the risk. 6, 16 In our study, we have shown that mild liver function abnormality prior to BMT does not increase the risk of post-BMT liver dysfunction, GVHD, or death. Eighteen out of 130 (13.8%) patients had elevated levels of ALT, total bilirubin, or alkaline phosphatase. We could not explain the etiology of the liver function abnormalities in 10 patients. There is some suggestion that iron overload may be a contributing factor to liver dysfunction prior to BMT especially in aplastic anemia patients. 17 Are patients who are HBs Ag positive or who have HCV antibody at increased risk of post-BMT liver dysfunction and death? Although patient numbers are small, our results suggest that there is no significant increase in the incidence of post-transplant liver dysfunction, GVHD, or death in these patients. This finding is in agreement with observations by some authors 6,9,10 but not by others. 7, 8 HBs Ag was detected 6 months and 9 months after BMT in two patients whose HBs Ag was negative prior to BMT. This could be due to blood transfusions in the early post-transplant period. On the other hand, a reactivation of latent HBV infection is also possible. 16 Hepatic GVHD occurs in 30-50% of BMT recipients and is a major cause of morbidity and mortality following BMT. 18, 19 This study also showed that the patients with hepatic GVHD had an increased incidence of death. Fulminant hepatic failure due to GVHD occurred in five of 41 (12.2%) hepatic GVHD patients.
In summary, we have shown that patients with mild liver dysfunction prior to BMT do not have an increased risk of post-transplant liver dysfunction, GVHD, or death. Patients who are HBs Ag positive or HCV antibody positive before BMT are also not at increased risk. GVHD and drug hepatotoxicity were major causes of liver dysfunction after BMT.
